Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Ultragenyx Pharmaceutical Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 examiners and 3 art units, indicating separate examination assignments.
BENAVIDES, JENNIFER ANN is the busiest examiner, with 1 pending matter. Counsel should coordinate the technical record across the matters while preparing responses tailored to each examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +48.2% |
| MOORE, JOHN DAVID | 1 | 61.1% | +28.3% |
| SIFFORD, JEFFREY MARK | 1 | 54.4% | +33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683819 | ANION-EXCHANGE CHROMATOGRAPHY METHODS FOR PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18696578 | METHODS OF USING ANTI-SCLEROSTIN ANTIBODIES IN TREATMENT OF OSTEOGENESIS IMPERFECTA | BENAVIDES, JENNIFER ANN | — |
| 18684333 | RECOMBINANT AAV FORMULATIONS | MOORE, JOHN DAVID | — |
| 18683819 | ANION-EXCHANGE CHROMATOGRAPHY METHODS FOR PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1638 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18696578 | METHODS OF USING ANTI-SCLEROSTIN ANTIBODIES IN TREATMENT OF OSTEOGENESIS IMPERFECTA | BENAVIDES, JENNIFER ANN | 1675 | §102§112DP | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18684333 | RECOMBINANT AAV FORMULATIONS | MOORE, JOHN DAVID | 1638 | §103 | Final Rejection | — | Pending | Feb 16, 2024 |
| 18683819 | ANION-EXCHANGE CHROMATOGRAPHY METHODS FOR PURIFICATION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES | SIFFORD, JEFFREY MARK | 1671 | §103§112 | Final Rejection | — | Pending | Feb 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUltragenyx Pharmaceutical Inc. has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Jennifer Ann Benavides has the most, with 1 of Ultragenyx Pharmaceutical Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.